14 / 17
Page 51
Notes:
conferenceseries
.com
Euro Pathology 2018 | Hematologic Oncology 2018
June 20-21, 2018
Volume 8
Journal of Clinical & Experimental Pathology
ISSN : 2161-0681
15
th
EUROPEAN PATHOLOGY CONGRESS
&
LEUKEMIA AND HEMATOLOGIC ONCOLOGY
June 20-21, 2018 | Paris, France
14
th
International Conference on
JOINT EVENT
Malignant mesothelioma and differential diagnosis with reactive mesothelial proliferation
Mark Podberezin
University of Saskatchewan, Canada
M
alignant mesothelioma (MM) is one of most lethal forms of cancer, causing about 3000 deaths per year in USA and 5000-
in Europe. Asbestos exposure is one of most important causative factor, and latency period after exposure can be as long as
40 years. Being tumor of serous membranes, it most commonly involves pleura, with minority of cases manifesting as peritoneal
mesothelioma. Despite recent advances in multimodality treatment, prognosis of MM patients is dismal, and average survival is
less than a year after diagnosis. Most common clinical presentation is unilateral recurring pleural hemorrhagic effusion. However,
depending on histologic variant, some patients do not have pleural effusion and present with shortness of breath and increased
pleural thickness. The latter is particularly true in sarcomatoid and desmoplastic variants of MM. Definitive diagnosis of MM can be
done on pleural biopsy based on combination of assessment of both morphologic and immunohistochemical findings, with the recent
inclusion of molecular cytogenetic findings in the diagnostic armamentarium. Most crucial and difficult task is to separate malignant
process from its benign mimics. And, despite all recent advances in the diagnosis of MM, differential diagnosis between MM and
reactive mesothelial proliferation remains major challenge. Importance of careful and thorough morphologic evaluation of growth
pattern cannot be overestimated. Presence of invasion is unequivocal criterion of malignancy while absence of definitive invasion
seen on the biopsy still cannot completely rule out MM. Therefore, other features, such as cellularity with cell distribution and
growth pattern, necrosis, and cytologic atypia have to be evaluated. Recent addition of BAP-1 immunostaining, as well as molecular
studies, has proven to be very helpful in differential diagnosis between MM and reactive mesothelial proliferation. Discussion of the
above diagnostic aspects is main focus of current presentation.
Biography
Mark Podberezin has completed his Post-doctoral Research Fellowship during the year 2001 from Children Hospital Los Angeles and University of Southern
California and Residency in Anatomic and Clinical Pathology at University of Illinois, Chicago. He has done the Fellowship in Hematopathology during the year
2013 from Texas Methodist Hospital. He is the Clinical Assistant Professor at University of Saskatchewan, Canada. He has published more than 12 papers in
reputed journals.
markpodberezin@att.netMark Podberezin, J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C1-045